Media coverage about RedHill Biopharma (NASDAQ:RDHL) has trended somewhat positive recently, Accern reports. Accern identifies positive and negative media coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. RedHill Biopharma earned a news sentiment score of 0.14 on Accern’s scale. Accern also assigned media coverage about the biotechnology company an impact score of 46.0449178147238 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.
These are some of the headlines that may have effected Accern’s scoring:
- RedHill Biopharma (RDHL) Scheduled to Post Earnings on Thursday (americanbankingnews.com)
- RedHill Biopharma to Host Fourth Quarter and Full-Year 2017 Financial Results Conference Call on February 22, 2018 – GlobeNewswire (press release) (globenewswire.com)
A number of equities analysts have recently weighed in on the company. Zacks Investment Research upgraded RedHill Biopharma from a “hold” rating to a “buy” rating and set a $5.50 target price on the stock in a research note on Friday, November 17th. Roth Capital cut their target price on RedHill Biopharma from $27.00 to $20.00 and set a “buy” rating on the stock in a research note on Tuesday, November 14th. HC Wainwright restated a “buy” rating and issued a $36.00 target price on shares of RedHill Biopharma in a research note on Tuesday, November 21st. Finally, Nomura initiated coverage on RedHill Biopharma in a research note on Friday, January 26th. They issued a “buy” rating and a $18.00 target price on the stock. One research analyst has rated the stock with a sell rating, one has issued a hold rating and five have given a buy rating to the stock. RedHill Biopharma has an average rating of “Buy” and a consensus price target of $20.58.
COPYRIGHT VIOLATION NOTICE: “Somewhat Positive News Coverage Somewhat Unlikely to Impact RedHill Biopharma (RDHL) Share Price” was first posted by Chaffey Breeze and is owned by of Chaffey Breeze. If you are viewing this article on another website, it was copied illegally and reposted in violation of United States and international copyright laws. The correct version of this article can be accessed at https://www.chaffeybreeze.com/2018/02/18/somewhat-positive-news-coverage-somewhat-unlikely-to-impact-redhill-biopharma-rdhl-share-price.html.
About RedHill Biopharma
Redhill Biopharma Ltd, is an Israel-based specialty biopharmaceutical company. The Company focuses on the development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for the treatment of gastrointestinal and inflammatory diseases and cancer. It offers the following gastrointestinal products in the United States: Donnatal, a prescription oral adjunctive drug used in the treatment of Irritable Bowel Syndrome (IBS) and acute enterocolitis, as well as EnteraGam, a medical food intended for the dietary management, under medical supervision, of chronic diarrhea and loose stools.
Receive News & Ratings for RedHill Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RedHill Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.